ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0968

Combined Inhibition of Autophagy and Glutamine Metabolism Suppresses Cell Growth of RA Synoviocytes and Ameliorates Arthritis in SKG Mice

Ikuko Naka1, Jun Saegusa2, Kenichi Uto2, Yuzuru Yamamoto3, Yoshihide Ichise4, Hirotaka Yamada4, Yo Ueda5, Takaichi Okano4, Soshi Takahashi6, Sho Sendo7 and Akio Morinobu8, 1Kobe University, Kobe, 2Department of Clinical Laboratory, Kobe University Hospital, Kobe, Japan, 3Kobe University, Kobe-city, Japan, 4Kobe University, Kobe, Japan, 5Kobe UniversityRheumatology and Clinical Immunology, Kobe University Hospital, Kobe, Japan, 6Kobe univerity, Kobe, Japan, 7Kobe university, Kobe city, Japan, 8Rheumatology and Clinical Immunology, Kobe University Hospital, Kobe, Japan

Meeting: ACR Convergence 2020

Keywords: Animal Model, Apoptosis, Fibroblasts, Synovial, rheumatoid arthritis, Synovitis

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 7, 2020

Title: RA – Animal Models (0965–0969)

Session Type: Abstract Session

Session Time: 5:00PM-5:50PM

Background/Purpose: Immunometabolism is now recognaized to be crucial in the pathogenesis of rheumatoid arthritis (RA). We have recently shown that the expression of glutaminase 1 (GLS1), a key enzyme in glutaminolysis, is upregulated in fibroblast-like synoviocytes from RA patients (RA-FLS) and that GLS1 inhibition suppresses RA-FLS proliferation (1). However, glutaminolysis has been known to suppress autophagy by activating mTORC1 or counteracting ROS production (2). Given the possibility of autophagy upregulation following glutamiolysis inhibition, therapies targeting both autophagy and glutaminolysis may be more effective in suppressing cell growth of RA-FLS, yet the relation between glutaminolysis and autophagy in RA-FLS has not been investigated. Here we examined the effects of inhibiting both glutaminolysis and autophagy on RA-FLS and autoimmune arthritis in SKG mice. 

Methods: GLS1 inhibitor, compound 968 (C968), was used to suppress glutaminolysis, and Chloroquine (CQ) was used to inhibit autophagy. To detect autophagy, the expression of ATG5 and LC3B was measured by real-time PCR and the production of LC3-Ⅱ was analyzed by Western blotting. The formation of autophagic vacuoles was identified by immunfluorescense. Cell growth was evaluated by BrdU assay. Apoptosis was analyzed by flow cytometry staining with Annexin V-FITC and PI. C968 and CQ were administered subcutaneously to Zymosan A-injected SKG mice.

Results: C968 upregulated the expression of ATG5 and LC3B, and increased the protein level of LC3-Ⅱ in RA-FLS. C968 also facilitated autophagosome formation. These results suggested that inhibition of glutaminolysis promoted autophagy in RA-FLS. The combined treatment with C968 and CQ significantly suppressed cell proliferation of RA-FLS more strongly than did C968 or CQ alone. In addition, C968 combined with CQ increased the apoptosis rate, whereas either C968 or CQ alone did not. Furthermore, combination of C968 and CQ significantly attenuated the degree of arthritis in SKG mice, while C968 or CQ monotherapy did not (Figure).

Conclusion: The GLS1 inhibitor C968 promotes autophagy in RA-FLS. C968 in combination with CQ reduces proliferation and enhances apoptosis in RA-FLS, and ameliorates the arthritis in SKG mice. Suppressing C968-induced autophagy may be a promising therapy for arthritis.

Combination of C968 and CQ significantly attenuated the degree of arthritis in SKG mice.


Disclosure: I. Naka, None; J. Saegusa, None; K. Uto, None; Y. Yamamoto, None; Y. Ichise, None; H. Yamada, None; Y. Ueda, None; T. Okano, None; S. Takahashi, None; S. Sendo, None; A. Morinobu, None.

To cite this abstract in AMA style:

Naka I, Saegusa J, Uto K, Yamamoto Y, Ichise Y, Yamada H, Ueda Y, Okano T, Takahashi S, Sendo S, Morinobu A. Combined Inhibition of Autophagy and Glutamine Metabolism Suppresses Cell Growth of RA Synoviocytes and Ameliorates Arthritis in SKG Mice [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/combined-inhibition-of-autophagy-and-glutamine-metabolism-suppresses-cell-growth-of-ra-synoviocytes-and-ameliorates-arthritis-in-skg-mice/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/combined-inhibition-of-autophagy-and-glutamine-metabolism-suppresses-cell-growth-of-ra-synoviocytes-and-ameliorates-arthritis-in-skg-mice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology